

Urinary Tract Pathogens (in Order of Frequency) - % Susceptible

| Organism | Number of Isolates | Amox clavulanic | Ampicillin | Cefazolin (1) | Ceftazidime | Ceftriaxone | Ciprofloxacin | Fosfomycin | Gentamicin | Meropenem | Nitrofurantoin | Trimethoprim- Sulfamethoxazole |
|--------------------------|--------------------------|-----------------|------------|-------------------|-------------|-------------------|-------------------|------------|-------------|-------------|----------------|-----------------------------------|
| E. coli ^ | 103 | 69 | 52 | 76 | | 77 | 58 | 94 | 91 | 100 | 99 | 83 |
| Klebsiella pneumoniae * | 50 | 92 n:49 | | 96 n:49 | | 96 n:49 | 88 n:49 | | 100 n:49 | 100 n:49 | 53 n:49 | 94 n:49 |
| Enterococcus species ^^^ | <30 | | | | | | | | | | | |
| Proteus mirabilis + | <30 | 79 n:19 | 63 n:19 | 84 n:19 | | 95 n:19 | 79 n:19 | | 89 n:19 | 100 n:19 | | 89 n:19 |
| Pseudomonas aeruginosa | <30 | | | | 88 n:16 | | 75 n:16 | | | | | |
| Group B Streptococcus ^^ | <30 | | | | | | | | | | | |

Organism Notes:

- * Includes ESBL and AMP-C isolates (4.0% of total Klebsiella pneumoniae isolates identified as ESBL and AMP-C).
- ^ Includes ESBL and AMP-C isolates (23.3% of total E.coli isolates identified as ESBL and AMP-C).
- ^ This isolate is predictably susceptible to Penicillin.

^^^ Clindamycin, Trimethoprim/Sulfamethoxazole and all Cephalosporins are ineffective against Enterococcus species. Enterococcus isolates recovered from urine are generally susceptible to amoxicillin and nitrofurantoin. Susceptibility to Amoxicillin is 97.9% and to Nitrofurantoin is 96.5%

+ Includes ESBL and AMP-C isolates (5.3% of total Proteus mirabilis isolates identified as ESBL and AMP-C).

Antibiotic Notes:

(1) Cefazolin interpretation predicts results for Cephalexin (Keflex) in accordance with CLSI standards for urinary sites only (not systemic).

All Other Specimen Types excluding (Urines and Surveillance) - Organisms in Order of Frequency - % Susceptible

| Organism | Number of Isolates | Cefazolin | Ceftazidime | Ciprofloxacin | Clindamycin | Cloxacillin | Erythromycin | Tetracycline (2) | Trimethoprim- Sulfamethoxazole |
|---------------------------|--------------------------|-------------------|-------------|---------------|----------------|-------------------|-------------------|------------------|-----------------------------------|
| Staphylococcus aureus ^^^ | 44 | 65 n:43 | | | 70 n:43 | 65 n:43 | 58 n:43 | 98 n:43 | 100 n:43 |
| Pseudomonas aeruginosa | 33 | | 88 | 76 | | | | | |
| Group B Streptococcus ^^ | <30 | | | | | | | | |

Organism Notes:

^ This isolate is predictably susceptible to Penicillin.

^ Includes Methicillin Resistant S.aureus (MRSA). MRSA is resistant to all B-Lactams (penicillins, cephalosporins, B-lactam/B-lactamase inhibitor combinations, and carbapenems). MRSA constitutes 34.1% of total Staphylococcus aureus isolates identified.

Antibiotic Notes:

(2) Organisms that are susceptible to Tetracycline are also considered susceptible to Doxycycline.

General Notes:

Antibiogram results, patient risk factors for resistant organisms, and resistance epidemiology should be considered together to help guide empiric treatment of initial infections. Treatment should be re-evaluated as additional information from culture and sensitivity become available.

Calculation of results based on first isolate per patient.

90-100% of isolates are susceptible to the antibiotic indicated (GOOD CHOICE)

21-89% of isolates are susceptible to the antibiotic indicated (INTERMEDIATE CHOICE)

0-20% of isolates are susceptible to the antibiotic indicated (POOR CHOICE)

Value based on < 30 isolates. Statistical comparison on results with less than 30 isolates is unreliable. n = # of isolates tested.

Antibiotic susceptibility testing is not typically performed on the organism.